Market Overview:
The global neuromyelitis optica (NMO) treatment market is expected to register a CAGR of XX% during the forecast period 2018-2030. The market growth can be attributed to factors such as increasing prevalence of NMO, rising awareness about NMO, and technological advancements in the field of NMO treatment. However, high cost associated with the treatment is expected to restrain the growth of this market during the forecast period. Based on type, the global neuromyelitis optica (NMO) treatment market is segmented into eculizumab, methylprednisolone, azathioprine, mycophenolate mofetil and rituximab. Eculizumab held a dominant position in 2017 and is projected to maintain its dominance throughout the forecast period. This can be attributed to its ability to inhibit complement activation which leads to damage caused by immune complexes in patients with NMOSD.
 Treatment Industry Outlook.svg)
Product Definition:
Devic's syndrome (neuromyelitis optica) is a rare autoimmune disorder that affects the nervous system. It causes inflammation and damage to the optic nerve and spinal cord. Symptoms may include vision loss, weakness or paralysis in the arms and legs, numbness, and extreme fatigue. Devic's syndrome is treated with corticosteroids to reduce inflammation and immunosuppressive drugs to suppress the immune system.
Eculizumab:
Eculizumab is an immunomodulating drug used for the treatment of relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis. It was approved by the U.S.
Methylprednisolone:
Methylprednisolone is a glucocorticoid. It is used in the treatment of neuromyelitis optica (NMO), also known as Devic’s syndrome. NMO affects one or more nerves that connect the eye, ear, and brain. The exact cause of NMO remains unknown; however, it may be related to an immune system problem that causes inflammation in the spinal cord and optic nerve.
Application Insights:
The others application segment held the largest share of over 70.0% in 2017. The others application category includes private clinics and hospitals as well as other healthcare facilities such as optical shops and pharmacies. Increasing awareness about NDO is positively influencing the adoption of these therapies, thereby driving the overall market growth. In addition, a rise in incidence rates of NDO is also expected to contribute to market growth during the forecast period due to its high prevalence rate globally (ranging between 1-2 per 100,000 population).
Based on applications, this industry has been further segmented into hospitals & clinics, private practices/hospitals.
Regional Analysis:
North America dominated the global devic’s syndrome treatment market in 2017. The presence of key players, favorable reimbursement scenario, and high adoption rate for new therapies are some factors responsible for its large share. In addition, higher healthcare expenditure and awareness levels among patients & physicians contribute to its largest revenue share.
Asia Pacific is expected to witness the fastest growth over the forecast period owing to unmet clinical needs coupled with rapidly improving healthcare infrastructure in emerging countries such as China & India. Moreover, increasing incidence of demyelinating diseases due to a rise in international travel will also drive regional growth during the forecast period (2018-2030).
Growth Factors:
- Increasing incidence of Devic's Syndrome (Neuromyelitis Optica)
- Growing awareness about the disease among people
- Rising demand for better and effective treatment options for Devic's Syndrome (Neuromyelitis Optica) patients
- Technological advancements in the field ofDevic's Syndrome (Neuromyelitis Optica) treatment
- Availability of government funding and support for research onDevic's Syndrome (Neuromyelitis Optica)
Scope Of The Report
Report Attributes
Report Details
Report Title
Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Research Report
By Type
Eculizumab, Methylprednisolone, Azathioprine, Mycophenolate Mofetil, Rituximab
By Application
Hospitals, Clinic, Others
By Companies
Alexion Pharmaceuticals, Inc., Teva Pharmaceuticals, Fresenius Kabi AG, Pharmacia & Upjohn (a subsidary of Pfizer), Lupin Ltd., Sagent Pharmaceuticals, Inc., Zydus Pharmaceuticals, Inc., Sandoz Inc. (Novartis), Alkem Laboratories Ltd., Mylan Pharmaceuticals, Inc., Hoffmann-La Roche/ Chugai Pharmaceutical, MedImmune LLC, RemeGen, Ltd.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
159
Number of Tables & Figures
112
Customization Available
Yes, the report can be customized as per your need.
Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Report Segments:
The global Devic’s Syndrome (Neuromyelitis Optica) Treatment market is segmented on the basis of:
Types
Eculizumab, Methylprednisolone, Azathioprine, Mycophenolate Mofetil, Rituximab
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Alexion Pharmaceuticals, Inc.
- Teva Pharmaceuticals
- Fresenius Kabi AG
- Pharmacia & Upjohn (a subsidary of Pfizer)
- Lupin Ltd.
- Sagent Pharmaceuticals, Inc.
- Zydus Pharmaceuticals, Inc.
- Sandoz Inc. (Novartis)
- Alkem Laboratories Ltd.
- Mylan Pharmaceuticals, Inc.
- Hoffmann-La Roche/ Chugai Pharmaceutical
- MedImmune LLC
- RemeGen, Ltd.
 Treatment Market Overview.svg)
Highlights of The Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Eculizumab
- Methylprednisolone
- Azathioprine
- Mycophenolate Mofetil
- Rituximab
- By Application:
- Hospitals
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Devic’s Syndrome (Neuromyelitis Optica) Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Treatment Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no cure for Devicu00e2u20acu2122s Syndrome, but there are treatments that can help improve the symptoms. Treatment may include medication, physical therapy, and/or surgery.
Some of the major companies in the devic’s syndrome (neuromyelitis optica) treatment market are Alexion Pharmaceuticals, Inc., Teva Pharmaceuticals, Fresenius Kabi AG, Pharmacia & Upjohn (a subsidary of Pfizer), Lupin Ltd., Sagent Pharmaceuticals, Inc., Zydus Pharmaceuticals, Inc., Sandoz Inc. (Novartis), Alkem Laboratories Ltd., Mylan Pharmaceuticals, Inc., Hoffmann-La Roche/ Chugai Pharmaceutical, MedImmune LLC, RemeGen, Ltd..
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Devic’s Syndrome (Neuromyelitis Optica) Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size & Forecast, 2018-2028
4.5.1 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size and Y-o-Y Growth
4.5.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Absolute $ Opportunity
Chapter 5 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Forecast by Type
5.2.1 Eculizumab
5.2.2 Methylprednisolone
5.2.3 Azathioprine
5.2.4 Mycophenolate Mofetil
5.2.5 Rituximab
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Forecast by Type
9.6.1 Eculizumab
9.6.2 Methylprednisolone
9.6.3 Azathioprine
9.6.4 Mycophenolate Mofetil
9.6.5 Rituximab
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Forecast by Type
10.6.1 Eculizumab
10.6.2 Methylprednisolone
10.6.3 Azathioprine
10.6.4 Mycophenolate Mofetil
10.6.5 Rituximab
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Forecast by Type
11.6.1 Eculizumab
11.6.2 Methylprednisolone
11.6.3 Azathioprine
11.6.4 Mycophenolate Mofetil
11.6.5 Rituximab
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Forecast by Type
12.6.1 Eculizumab
12.6.2 Methylprednisolone
12.6.3 Azathioprine
12.6.4 Mycophenolate Mofetil
12.6.5 Rituximab
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Devic’s Syndrome (Neuromyelitis Optica) Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Forecast by Type
13.6.1 Eculizumab
13.6.2 Methylprednisolone
13.6.3 Azathioprine
13.6.4 Mycophenolate Mofetil
13.6.5 Rituximab
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market: Competitive Dashboard
14.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Alexion Pharmaceuticals, Inc.
14.3.2 Teva Pharmaceuticals
14.3.3 Fresenius Kabi AG
14.3.4 Pharmacia & Upjohn (a subsidary of Pfizer)
14.3.5 Lupin Ltd.
14.3.6 Sagent Pharmaceuticals, Inc.
14.3.7 Zydus Pharmaceuticals, Inc.
14.3.8 Sandoz Inc. (Novartis)
14.3.9 Alkem Laboratories Ltd.
14.3.10 Mylan Pharmaceuticals, Inc.
14.3.11 Hoffmann-La Roche/ Chugai Pharmaceutical
14.3.12 MedImmune LLC
14.3.13 RemeGen, Ltd.
